Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.


TSX:FRX - Post by User

Comment by Brinkleyon Jul 07, 2017 6:59am
265 Views
Post# 26443351

RE:RE:RE:Financing with new investor

RE:RE:RE:Financing with new investorThere is no short answer for that.  Everything seems to be lining up great for them though. 

Small number of shares tightly held. (Including my own) 

2nd Phase 3 trial results to be released soon.  

Safty results of 2 phase 3 trials show it is safe

efficacy in all trials to date shows that it protects hearing substantially. 

Many companies looking for drugs rugs to fill the pipeline. 

Potential for a or a priority voucher worth over 100 million. 

Substantial amount of historic cost cost to offset future income. 


From there here it's just math. Future cash flows discounted back to today. You can easily get 20 to 30 dollars USD. 

I expect they they will sell in the next 12 months for something in that range. 

Just my opinion though. 


Bullboard Posts